Sequent Scientific Limited - Asset Resilience Ratio
Sequent Scientific Limited (SEQUENT) has an Asset Resilience Ratio of 0.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SEQUENT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Sequent Scientific Limited's Asset Resilience Ratio has changed over time. See SEQUENT net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sequent Scientific Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SEQUENT company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs14.50 Million | 0.08% |
| Total Liquid Assets | Rs14.50 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: Sequent Scientific Limited maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sequent Scientific Limited Industry Peers by Asset Resilience Ratio
Compare Sequent Scientific Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Sequent Scientific Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Sequent Scientific Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.03% | Rs4.18 Million ≈ $45.21K |
Rs16.02 Billion ≈ $173.24 Million |
-0.23pp |
| 2024-03-31 | 0.26% | Rs39.75 Million ≈ $429.88K |
Rs15.40 Billion ≈ $166.59 Million |
+0.26pp |
| 2023-03-31 | 0.00% | Rs460.00K ≈ $4.97K |
Rs15.29 Billion ≈ $165.37 Million |
-0.11pp |
| 2022-03-31 | 0.11% | Rs16.25 Million ≈ $175.74K |
Rs14.51 Billion ≈ $156.92 Million |
-0.32pp |
| 2021-03-31 | 0.43% | Rs59.59 Million ≈ $644.44K |
Rs13.93 Billion ≈ $150.60 Million |
-2.32pp |
| 2020-03-31 | 2.75% | Rs401.79 Million ≈ $4.35 Million |
Rs14.63 Billion ≈ $158.18 Million |
+2.71pp |
| 2019-03-31 | 0.03% | Rs4.70 Million ≈ $50.83K |
Rs13.88 Billion ≈ $150.09 Million |
-1.26pp |
| 2018-03-31 | 1.29% | Rs173.45 Million ≈ $1.88 Million |
Rs13.43 Billion ≈ $145.21 Million |
-2.14pp |
| 2017-03-31 | 3.43% | Rs653.76 Million ≈ $7.07 Million |
Rs19.05 Billion ≈ $205.98 Million |
-0.95pp |
| 2016-03-31 | 4.38% | Rs669.78 Million ≈ $7.24 Million |
Rs15.28 Billion ≈ $165.26 Million |
+4.32pp |
| 2015-03-31 | 0.06% | Rs5.81 Million ≈ $62.83K |
Rs9.08 Billion ≈ $98.16 Million |
+0.05pp |
| 2014-03-31 | 0.01% | Rs770.00K ≈ $8.33K |
Rs6.23 Billion ≈ $67.34 Million |
-0.02pp |
| 2013-03-31 | 0.03% | Rs1.77 Million ≈ $19.14K |
Rs5.86 Billion ≈ $63.40 Million |
-0.02pp |
| 2012-03-31 | 0.05% | Rs2.77 Million ≈ $29.96K |
Rs5.47 Billion ≈ $59.19 Million |
-0.18pp |
| 2011-03-31 | 0.23% | Rs10.25 Million ≈ $110.85K |
Rs4.50 Billion ≈ $48.65 Million |
-4.31pp |
| 2006-03-31 | 4.54% | Rs12.46 Million ≈ $134.71K |
Rs274.60 Million ≈ $2.97 Million |
-- |
About Sequent Scientific Limited
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was former… Read more